-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Point: Yes, That is the Only Way We Can Cure Myeloma?

Program: Spotlight Sessions
Session: Smoldering Myeloma: A Case for Early Intervention?
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Translational Research, Clinical Research, Plasma Cell Disorders, Education, Diseases, Registries, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease
Monday, December 9, 2024, 10:30 AM-11:45 AM

Maria-Victoria Mateos, MD, PhD

Hematology Department, University Hospital of Salamanca, Salamanca, Spain

Disclosures: Mateos: AbbVie, Amgen, Bluebird bio, Celgene, GlaxoSmithKline, Janssen, Kite, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Stemline, and Takeda: Honoraria.

OffLabel Disclosure: There is not any drug approved in Smoldering Myeloma so all drugs mentioned in the presentation are off-label

See more of: Smoldering Myeloma: A Case for Early Intervention?
See more of: Spotlight Sessions
Previous Presentation | Next Presentation >>